secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001437749-22-027041
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree Q3 net loss $4.1M, licenses KL4 surfactant globally for up to $78.9M milestones
--------------------------------------------------------------------------------

- Net loss of $4.1M ($0.13 per share) vs $8.2M loss in Q3 2021; operating loss $4.7M vs $8.1M.
- R&D expenses fell to $1.5M from $4.7M as focus shifts to istaroxime; G&A decreased to $2.7M.
- Global license to Lee's (HK)/Zhaoke for KL4 surfactant platform; up to $78.9M milestones plus double-digit royalties.
- Cash $8.4M at Sept 30, expected to fund operations into Q2 2023.
- USPTO allowed istaroxime patent for longer infusions; positive SEISMiC study published in European Journal of Heart Failure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774922027041/0001437749-22-027041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774922027041/wint20220823_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-027041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer